Mainstay Medical
Mainstay Medical is developing ReActiv8, an implantable peripheral nerve stimulator system leveraging a novel neurorehabilitation therapy approach to treat chronic, non-specific, low back pain. Chronic low back pain is a major unmet medical problem afflicting millions of people world-wide each year, where conventional therapies have limited effectiveness for the majority of patients. Both the Capital Fund and the Crossover Fund have invested in Mainstay.
Sector
Medical Devices
Strategies
Capital & Crossover
Status
Live
Website
mainstaymedical.com
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Cedric Moreau
Partner, Sofinnova Partners - Crossover Strategy
Related News
Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®
Mainstay Medical announces receipt of European and Australian approvals of MRI labeling on ReActiv8® Restorative Neurostimulation System™
Mainstay Medical announces publication of the first neuromodulation study for low back pain with 5-year follow-up
Mainstay Medical announces publication of clinical results comparing older patients and younger patients
Mainstay Medical announces US$125 million equity financing transaction
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.